Breaking News for May 3, 2004 issue
PCV13 Significantly Reduces Invasive Pneumococcal Disease in Pediatric Patients
Researchers explore trends from 2014 to 2022 among pediatric invasive pneumococcal diseases since introduction of the 13-valent pneumococcal conjugate vaccine.
How LucyRx is Changing the Traditional PBM Model
LucyRx is empowering pharmacists and impacting patients’ health outcomes with its business model unlike other market-leading pharmacy benefit managers.
Orforglipron Shows Superior Reduction in Hemoglobin A1c for Patients With Type 2 Diabetes
Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.
The Rise in Direct-to-Consumer Advertising of Prescription Drugs
Throughout her research, Jenny Markell, BA, has uncovered some alarming trends within prescription drug advertising in the US.
Expert Discusses Transparency and Education for the Current Measles Outbreak
Crystal Hodge discusses being transparent about adverse effects of the MMR vaccine and educating patients about measles.
FDA Approves Dupilumab for Treatment of Chronic Spontaneous Urticaria
The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.
